The global primary hepatocytes market is poised for significant growth, projected to reach a value of US$ 410 Mn by 2031, with an estimated Compound Annual Growth Rate (CAGR) of 8.0% over the next decade. This promising trajectory reflects the increasing demand for primary hepatocytes, driven by their crucial role in drug development, testing, and the development of new cancer treatments.

Opportunities for Primary Hepatocyte Manufacturers:

The routine adoption of hepatocytes for analyzing potential medication candidates accelerates the development of novel medicines and expedites their entry into clinical trials. The reliability of testing models significantly influences the success of developing novel medication therapies, emphasizing the pivotal role of hepatocytes in this process.

Advancements in technology are progressively reducing the reliance on animal models, favoring increasingly in vivo-like systems. This trend is expected to drive the demand for primary hepatocytes in the foreseeable future.

The growing prevalence of cancer and the escalating demand for cancer therapy have spurred research involving primary hepatocytes. Personalized medicine, which offers tailored treatment options based on individual patient characteristics, relies on primary hepatocytes for the development of personalized medications. Consequently, the market for primary hepatocytes has witnessed parallel growth alongside the rise in demand for personalized therapeutics.

Liver transplantation remains the optimal treatment for hepatic illness caused by various factors such as viruses, oncogenes, medications, or surgical removal. However, the scarcity of suitable liver donors presents challenges in meeting medical demands. To address this issue, alternative options such as hepatocyte transplantation are being explored, driving immediate demand for primary hepatocytes and fostering market development.

Stringent regulations set by various regulatory bodies emphasize ensuring the well-being of animals used in experiments. These regulations, coupled with researchers' self-imposed limits, have led to an increased demand for in-vivo models, presenting opportunities for primary hepatocyte providers to meet these regulatory standards and cater to the growing market demand.

Challenges Impacting Demand:

Despite the promising growth outlook, challenges persist in maintaining the demand for primary hepatocytes. Availability of other cell types for drug screening, along with the high risk of contamination and the intricate maintenance requirements of hepatocytes, pose constraints on market expansion. Additionally, the limited lifespan of freshly-isolated hepatocytes and the susceptibility to contamination hinder their widespread adoption.

Country-wise Insights:

United States: With approximately 84.7% market share in the North American primary hepatocytes culture market, the U.S. presents a lucrative landscape fueled by increasing investments in R&D programs and strategic business expansions.
Germany: Holding the largest market share in Europe, Germany benefits from the presence of major industry players, fostering accessibility and steady growth in the primary hepatocytes market.
China: Emerging as a prominent market, China exhibits substantial growth potential driven by extensive research activities, collaborative initiatives, and significant R&D investments.
India: With a considerable share in the South Asia primary hepatocytes market, India showcases a growing adoption of modern medicines and newer therapies, supported by increasing affordability and acceptance of biological drugs.

Competitive Landscape: Leading providers such as Thermo Fisher Scientific, Corning Inc., Lonza, and others are strategically positioning themselves through alliances, product launches, patents, and acquisitions to capitalize on the burgeoning opportunities in the primary hepatocytes industry.

Key Companies Profiled in the market include:

Thermo Fisher Scientific
Corning Inc.
Lonza
Axol Bioscience Ltd.
LifeNet Health
SEKISUI XenoTech, LLC
Cytes Biotechnologies
Cell Biologics, Inc.
ZenBio, Inc.
BioIVT.
ScienCell Research Laboratories, Inc.
Kerafast
Takara Bio Inc.
Kosheeka

Key Segments Covered in Primary Hepatocytes Industry Survey

Primary Hepatocytes Market by Product:

Cryopreserved Suspension Hepatocytes
Fresh Suspension Hepatocytes
3D (Spheroid) Hepatocytes
Expanded Hepatocytes (Plateable)
Non-characterized Hepatocytes

Primary Hepatocytes Market by Species:

Humans
Rats
Mice
Dogs
Monkeys
Horses
Others

Primary Hepatocytes Market by Application or Assay:

Cell Viability Assays
Cytochrome Enzyme Activity
High Content Cytotoxicity
Transporter Inhibition Assays
In Vitro Intrinsic Clearance
Phospholipoids Assays
Others

Primary Hepatocytes Market by End User:

Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organizations

Primary Hepatocytes Market by Region:

North America Primary Hepatocytes Market
Latin America Primary Hepatocytes Market
Europe Primary Hepatocytes Market
South Asia Primary Hepatocytes Market
East Asia Primary Hepatocytes Market
Oceania Primary Hepatocytes Market
The Middle East & Africa Primary Hepatocytes Market

1. Executive Summary

1.1. Global Primary Hepatocytes Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

3.1. Global Primary Hepatocytes Market Production Output, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2023
- 3.1.1. North America
- 3.1.2. Europe x`
- 3.1.3. Asia Pacific
- 3.1.4. Latin America
- 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

4.1. Global Average Price Analysis, by Product/ Species/ Application or Assay/ End User, US$ Per Unit, 2018 - 2023
4.2. Prominent Factor Affecting Primary Hepatocytes Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Primary Hepatocytes Market Outlook, 2018 - 2031

5.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Cryopreserved Suspension Hepatocytes
  - 5.1.1.2. Fresh Suspension Hepatocytes
  - 5.1.1.3. 3D (Spheroid) Hepatocytes
  - 5.1.1.4. Expanded Hepatocytes (Plateable)
  - 5.1.1.5. Non-characterized Hepatocytes
5.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Humans
  - 5.2.1.2. Rats
  - 5.2.1.3. Mice
  - 5.2.1.4. Dogs
  - 5.2.1.5. Monkeys
  - 5.2.1.6. Horses
  - 5.2.1.7. Others
5.3. Global Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Cell Viability Assays
  - 5.3.1.2. Cytochrome Enzyme Activity
  - 5.3.1.3. High Content Cytotoxicity
  - 5.3.1.4. Transporter Inhibition Assays
  - 5.3.1.5. In Vitro Intrinsic Clearance
  - 5.3.1.6. Phospholipoids Assays
  - 5.3.1.7. Others
5.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Biopharmaceutical Companies
  - 5.4.1.2. Academic and Research Institutes
  - 5.4.1.3. Contract Research Organizations
5.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. North America
  - 5.5.1.2. Europe
  - 5.5.1.3. Asia Pacific
  - 5.5.1.4. Latin America
  - 5.5.1.5. Middle East & Africa

6. North America Primary Hepatocytes Market Outlook, 2018 - 2031

6.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Cryopreserved Suspension Hepatocytes
  - 6.1.1.2. Fresh Suspension Hepatocytes
  - 6.1.1.3. 3D (Spheroid) Hepatocytes
  - 6.1.1.4. Expanded Hepatocytes (Plateable)
  - 6.1.1.5. Non-characterized Hepatocytes
6.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Humans
  - 6.2.1.2. Rats
  - 6.2.1.3. Mice
  - 6.2.1.4. Dogs
  - 6.2.1.5. Monkeys
  - 6.2.1.6. Horses
  - 6.2.1.7. Others
6.3. North America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Cell Viability Assays
  - 6.3.1.2. Cytochrome Enzyme Activity
  - 6.3.1.3. High Content Cytotoxicity
  - 6.3.1.4. Transporter Inhibition Assays
  - 6.3.1.5. In Vitro Intrinsic Clearance
  - 6.3.1.6. Phospholipoids Assays
  - 6.3.1.7. Others
6.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Biopharmaceutical Companies
  - 6.4.1.2. Academic and Research Institutes
  - 6.4.1.3. Contract Research Organizations
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 6.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 6.5.1.3. U.S. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 6.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 6.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 6.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 6.5.1.7. Canada Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 6.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Primary Hepatocytes Market Outlook, 2018 - 2031

7.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Cryopreserved Suspension Hepatocytes
  - 7.1.1.2. Fresh Suspension Hepatocytes
  - 7.1.1.3. 3D (Spheroid) Hepatocytes
  - 7.1.1.4. Expanded Hepatocytes (Plateable)
  - 7.1.1.5. Non-characterized Hepatocytes
7.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Humans
  - 7.2.1.2. Rats
  - 7.2.1.3. Mice
  - 7.2.1.4. Dogs
  - 7.2.1.5. Monkeys
  - 7.2.1.6. Horses
  - 7.2.1.7. Others
7.3. Europe Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Cell Viability Assays
  - 7.3.1.2. Cytochrome Enzyme Activity
  - 7.3.1.3. High Content Cytotoxicity
  - 7.3.1.4. Transporter Inhibition Assays
  - 7.3.1.5. In Vitro Intrinsic Clearance
  - 7.3.1.6. Phospholipoids Assays
  - 7.3.1.7. Others
7.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Biopharmaceutical Companies
  - 7.4.1.2. Academic and Research Institutes
  - 7.4.1.3. Contract Research Organizations
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.3. Germany Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.7. U.K. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.11. France Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.13. Italy Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.14. Italy Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.15. Italy Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.16. Italy Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.17. Turkey Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.18. Turkey Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.19. Turkey Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.20. Turkey Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.23. Russia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.27. Rest of Europe Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 7.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Primary Hepatocytes Market Outlook, 2018 - 2031

8.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Cryopreserved Suspension Hepatocytes
  - 8.1.1.2. Fresh Suspension Hepatocytes
  - 8.1.1.3. 3D (Spheroid) Hepatocytes
  - 8.1.1.4. Expanded Hepatocytes (Plateable)
  - 8.1.1.5. Non-characterized Hepatocytes
8.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Humans
  - 8.2.1.2. Rats
  - 8.2.1.3. Mice
  - 8.2.1.4. Dogs
  - 8.2.1.5. Monkeys
  - 8.2.1.6. Horses
  - 8.2.1.7. Others
8.3. Asia Pacific Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Cell Viability Assays
  - 8.3.1.2. Cytochrome Enzyme Activity
  - 8.3.1.3. High Content Cytotoxicity
  - 8.3.1.4. Transporter Inhibition Assays
  - 8.3.1.5. In Vitro Intrinsic Clearance
  - 8.3.1.6. Phospholipoids Assays
  - 8.3.1.7. Others
8.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Biopharmaceutical Companies
  - 8.4.1.2. Academic and Research Institutes
  - 8.4.1.3. Contract Research Organizations
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Asia Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.3. China Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.7. Japan Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.11. South Korea Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.15. India Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.19. Southeast Asia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 8.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Primary Hepatocytes Market Outlook, 2018 - 2031

9.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 9.1.1. Key Highlights
  - 9.1.1.1. Cryopreserved Suspension Hepatocytes
  - 9.1.1.2. Fresh Suspension Hepatocytes
  - 9.1.1.3. 3D (Spheroid) Hepatocytes
  - 9.1.1.4. Expanded Hepatocytes (Plateable)
  - 9.1.1.5. Non-characterized Hepatocytes
9.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 9.2.1. Key Highlights
  - 9.2.1.1. Humans
  - 9.2.1.2. Rats
  - 9.2.1.3. Mice
  - 9.2.1.4. Dogs
  - 9.2.1.5. Monkeys
  - 9.2.1.6. Horses
  - 9.2.1.7. Others
9.3. Latin America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 9.3.1. Key Highlights
  - 9.3.1.1. Cell Viability Assays
  - 9.3.1.2. Cytochrome Enzyme Activity
  - 9.3.1.3. High Content Cytotoxicity
  - 9.3.1.4. Transporter Inhibition Assays
  - 9.3.1.5. In Vitro Intrinsic Clearance
  - 9.3.1.6. Phospholipoids Assays
  - 9.3.1.7. Others
9.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 9.4.1. Key Highlights
  - 9.4.1.1. Biopharmaceutical Companies
  - 9.4.1.2. Academic and Research Institutes
  - 9.4.1.3. Contract Research Organizations
- 9.4.2. BPS Analysis/Market Attractiveness Analysis
9.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 9.5.1. Key Highlights
  - 9.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.3. Brazil Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.7. Mexico Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.9. Argentina Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.10. Argentina Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.11. Argentina Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.12. Argentina Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.13. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.14. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.15. Rest of Latin America Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 9.5.1.16. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Primary Hepatocytes Market Outlook, 2018 - 2031

10.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 10.1.1. Key Highlights
  - 10.1.1.1. Cryopreserved Suspension Hepatocytes
  - 10.1.1.2. Fresh Suspension Hepatocytes
  - 10.1.1.3. 3D (Spheroid) Hepatocytes
  - 10.1.1.4. Expanded Hepatocytes (Plateable)
  - 10.1.1.5. Non-characterized Hepatocytes
10.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 10.2.1. Key Highlights
  - 10.2.1.1. Humans
  - 10.2.1.2. Rats
  - 10.2.1.3. Mice
  - 10.2.1.4. Dogs
  - 10.2.1.5. Monkeys
  - 10.2.1.6. Horses
  - 10.2.1.7. Others
10.3. Middle East & Africa Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 10.3.1. Key Highlights
  - 10.3.1.1. Cell Viability Assays
  - 10.3.1.2. Cytochrome Enzyme Activity
  - 10.3.1.3. High Content Cytotoxicity
  - 10.3.1.4. Transporter Inhibition Assays
  - 10.3.1.5. In Vitro Intrinsic Clearance
  - 10.3.1.6. Phospholipoids Assays
  - 10.3.1.7. Others
10.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 10.4.1. Key Highlights
  - 10.4.1.1. Biopharmaceutical Companies
  - 10.4.1.2. Academic and Research Institutes
  - 10.4.1.3. Contract Research Organizations
- 10.4.2. BPS Analysis/Market Attractiveness Analysis
10.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 10.5.1. Key Highlights
  - 10.5.1.1. GCC Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.2. GCC Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.3. GCC Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.4. GCC Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.7. South Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.8. South Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.9. Egypt Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.10. Egypt Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.11. Egypt Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.12. Egypt Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.15. Nigeria Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
  - 10.5.1.20. Rest of Middle East & Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
- 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

11.1. Product vs Application or Assay Heatmap
11.2. Company Market Share Analysis, 2022
11.3. Competitive Dashboard
11.4. Company Profiles
- 11.4.1. Thermo Fisher Scientific
  - 11.4.1.1. Company Overview
  - 11.4.1.2. Product Portfolio
  - 11.4.1.3. Financial Overview
  - 11.4.1.4. Business Strategies and Development
- 11.4.2. Corning Inc.
  - 11.4.2.1. Company Overview
  - 11.4.2.2. Product Portfolio
  - 11.4.2.3. Financial Overview
  - 11.4.2.4. Business Strategies and Development
- 11.4.3. Lonza
  - 11.4.3.1. Company Overview
  - 11.4.3.2. Product Portfolio
  - 11.4.3.3. Financial Overview
  - 11.4.3.4. Business Strategies and Development
- 11.4.4. Axol Bioscience Ltd.
  - 11.4.4.1. Company Overview
  - 11.4.4.2. Product Portfolio
  - 11.4.4.3. Financial Overview
  - 11.4.4.4. Business Strategies and Development
- 11.4.5. LifeNet Health
  - 11.4.5.1. Company Overview
  - 11.4.5.2. Product Portfolio
  - 11.4.5.3. Financial Overview
  - 11.4.5.4. Business Strategies and Development
- 11.4.6. SEKISUI XenoTech, LLC
  - 11.4.6.1. Company Overview
  - 11.4.6.2. Product Portfolio
  - 11.4.6.3. Financial Overview
  - 11.4.6.4. Business Strategies and Development
- 11.4.7. Cytes Biotechnologies
  - 11.4.7.1. Company Overview
  - 11.4.7.2. Product Portfolio
  - 11.4.7.3. Financial Overview
  - 11.4.7.4. Business Strategies and Development
- 11.4.8. Cell Biologics, Inc.
  - 11.4.8.1. Company Overview
  - 11.4.8.2. Product Portfolio
  - 11.4.8.3. Financial Overview
  - 11.4.8.4. Business Strategies and Development
- 11.4.9. ZenBio, Inc.
  - 11.4.9.1. Company Overview
  - 11.4.9.2. Product Portfolio
  - 11.4.9.3. Financial Overview
  - 11.4.9.4. Business Strategies and Development
- 11.4.10. BioIVT.
  - 11.4.10.1. Company Overview
  - 11.4.10.2. Product Portfolio
  - 11.4.10.3. Financial Overview
  - 11.4.10.4. Business Strategies and Development
- 11.4.11. ScienCell Research Laboratories, Inc.
  - 11.4.11.1. Company Overview
  - 11.4.11.2. Product Portfolio
  - 11.4.11.3. Financial Overview
  - 11.4.11.4. Business Strategies and Development
- 11.4.12. Kerafast
  - 11.4.12.1. Company Overview
  - 11.4.12.2. Product Portfolio
  - 11.4.12.3. Financial Overview
  - 11.4.12.4. Business Strategies and Development